Items Tagged ‘Tafinlar (dabrafenib)’

March 15th, 2017

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma


For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapy are alive versus 31% of patients on BRAF monotherapy with […]

View full entry

Tags: BRAF, mek, Mekinist (trametinib), Melanoma, News, Tafinlar (dabrafenib), Zelboraf (vemurafenib